中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
21期
12-15
,共4页
激活受体γ%p21%自发性高血压大鼠%左室肥厚%阿托伐他汀
激活受體γ%p21%自髮性高血壓大鼠%左室肥厚%阿託伐他汀
격활수체γ%p21%자발성고혈압대서%좌실비후%아탁벌타정
Peroxisome proliferator-activated receptor-γ%P21%Spontaneously hypertensive rats%Left ventricular hypertrophy%Atorvastatin
目的：应用阿托伐他汀抑制自发性高血压大鼠出现左室肥厚心肌过氧化物酶体增殖物激活受体γ（PPARγ）和p21表达及其改善机制。方法随机将同批次16只具有8周龄的自发性高血压大鼠分为阿托伐他汀ATV组与自发性高血压SHR组（各8只）；另选取8只同周龄大鼠作为正常血压WKY组。采用阿托伐他汀对ATV组进行灌胃，50 mg/（kg·d）；对SHR组与WKY组进行等容量蒸馏水灌胃，测量3组大鼠血压，5周/次；持续干预10周后，对其血压及血脂水平进行观察与测量，同时计算其心肌肥厚指标，并使用RT-PCR、免疫组化观察PPARγ和p21的表达。结果血脂及血压观测结果显示，SHR组与ATV组无显著差异，ATV组心肌肥厚指标明显低于SHR组，差异有统计学意义（P<0.01）；ATV组PPARγ和p21的表达明显高于SHR组，差异有统计学意义(P<0.01)。心肌组织PPARγ和p21 mRNA的表达表现出负相关性。结论阿托伐他汀可自行对自发性高血压大鼠心肌细胞中PPARγ、p21上调以对细胞周期进行调节，对高血压左室肥厚具有改善作用。
目的：應用阿託伐他汀抑製自髮性高血壓大鼠齣現左室肥厚心肌過氧化物酶體增殖物激活受體γ（PPARγ）和p21錶達及其改善機製。方法隨機將同批次16隻具有8週齡的自髮性高血壓大鼠分為阿託伐他汀ATV組與自髮性高血壓SHR組（各8隻）；另選取8隻同週齡大鼠作為正常血壓WKY組。採用阿託伐他汀對ATV組進行灌胃，50 mg/（kg·d）；對SHR組與WKY組進行等容量蒸餾水灌胃，測量3組大鼠血壓，5週/次；持續榦預10週後，對其血壓及血脂水平進行觀察與測量，同時計算其心肌肥厚指標，併使用RT-PCR、免疫組化觀察PPARγ和p21的錶達。結果血脂及血壓觀測結果顯示，SHR組與ATV組無顯著差異，ATV組心肌肥厚指標明顯低于SHR組，差異有統計學意義（P<0.01）；ATV組PPARγ和p21的錶達明顯高于SHR組，差異有統計學意義(P<0.01)。心肌組織PPARγ和p21 mRNA的錶達錶現齣負相關性。結論阿託伐他汀可自行對自髮性高血壓大鼠心肌細胞中PPARγ、p21上調以對細胞週期進行調節，對高血壓左室肥厚具有改善作用。
목적：응용아탁벌타정억제자발성고혈압대서출현좌실비후심기과양화물매체증식물격활수체γ（PPARγ）화p21표체급기개선궤제。방법수궤장동비차16지구유8주령적자발성고혈압대서분위아탁벌타정ATV조여자발성고혈압SHR조（각8지）；령선취8지동주령대서작위정상혈압WKY조。채용아탁벌타정대ATV조진행관위，50 mg/（kg·d）；대SHR조여WKY조진행등용량증류수관위，측량3조대서혈압，5주/차；지속간예10주후，대기혈압급혈지수평진행관찰여측량，동시계산기심기비후지표，병사용RT-PCR、면역조화관찰PPARγ화p21적표체。결과혈지급혈압관측결과현시，SHR조여ATV조무현저차이，ATV조심기비후지표명현저우SHR조，차이유통계학의의（P<0.01）；ATV조PPARγ화p21적표체명현고우SHR조，차이유통계학의의(P<0.01)。심기조직PPARγ화p21 mRNA적표체표현출부상관성。결론아탁벌타정가자행대자발성고혈압대서심기세포중PPARγ、p21상조이대세포주기진행조절，대고혈압좌실비후구유개선작용。
Objective To investigate the effect of atorvastatin on peroxisome proliferator-activated receptor-γ (PPARγ) and p21 expression of hypertrophic myocardium in spontaneously hypertensive rats and discuss the underlying mechanisms which atorvastatin improves left ventricular hypertrophy. Methods 16 eight-week-old male spontaneously hypertensive rats were randomly divided into atorvastatin group (ATV group, n=8) and spontaneously hypertensive rats group (SHR group, n=8). Age–matched Wistar - kyoto rats were served as normal blood pressure control group (WKY group, n=8). In ATV group, atorvastatin was given at a dose of 50 mg/(kg·d) perday by gastric gavage, and in SHR and WKY group, the same volume of distilled water by gavage. Measure the blood pressure every five weeks. Ten weeks later, blood pressure and plasma lipid levels were measured. The ratio of the heart weight to body weight (HW/BW) and the left ventricular weight to body weight (LVW/BW) were calculated as myocardial hypertrophy index. The expressions of PPARγ and p21 were investigated by the method of immunohistochemistry analysis and RT-PCR. Results There was not much difference of plasma lipid levels and blood pressure between ATV and SHR group. Compared with SHR group, Myocardial hypertrophy index decreased significantly in ATV group (P<0.01). The myocardium PPARγand p21 expression increased significantly (P<0.01). The association between expression of PPARγmRNA and p21mRNA in cardiomyocytes and myocardial hypertrophy index are negative correlation. Conclusion Atorvastatin increases myocardium PPARγand P21 expression and improves left ventricular hypertrophy in spontaneously hypertensive rats.
